{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:58:17Z","timestamp":1790859497525,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effects of prostate cancer screening compared to no screening in men with no prior diagnosis of prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review represents an update of a prior Cochrane review from 2013, searching multiple databases up to November 2025. We included randomised controlled trials (RCTs) of prostate cancer screening vs no screening. We used standard Cochrane methods, including rating the certainty of the evidence following a Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six RCTs (789\u2009086 participants; follow\u2010up 3.2\u201323\u2009years) were included: five evaluated prostate\u2010specific antigen (PSA)\u2010alone screening; one evaluated PSA combined with a kallikrein panel and magnetic resonance imaging (MRI) (ProScreen). Results are based on the certainty of evidence for each outcome and are therefore mainly derived from a sensitivity analysis by risk of bias, using the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial: screening likely results in a reduction in prostate cancer\u2010specific mortality (sensitivity analysis from ERSPC: risk ratio [RR] 0.87, 95% confidence interval [CI] 0.80\u20130.95; one study, 162\u2009236 participants; moderate\u2010certainty evidence; minimal clinically important difference [MCID]: one per 1000 participants). Assuming a baseline risk of 16 prostate\u2010cancer\u2010related deaths per 1000, this corresponds to two fewer (95% CI three fewer to one fewer) per 1000. Based on the analysis that included all eligible trials, screening may reduce overall mortality, although the CI includes the possibility of little to no effect (RR 0.99, 95% CI 0.97\u20131.00;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u200922%; four studies, 675\u2009121 participants; low\u2010certainty evidence; MCID: one per 1000 participants). Assuming a baseline risk of 491 deaths from any cause per 1000, this corresponds to five fewer (95% CI 15 fewer to 0 fewer) per 1000. Screening may result in little to no difference in adverse events (RR 1.32, 95% CI 0.48\u20133.65; low certainty) or quality of life. In the ProScreen trial (60\u2009745 participants, 3.2\u2010year follow\u2010up), combined screening probably has little to no effect on overall detection (RR 1.85, 95% CI 1.56\u20132.19; moderate certainty), localised detection (RR 1.88, 95% CI 1.55\u20132.27; moderate certainty), or advanced detection (RR 1.78, 95% CI 1.19\u20132.66; moderate certainty). Mortality data are not yet mature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Screening likely reduces prostate cancer\u2010specific mortality and may reduce overall mortality. It may have little to no effect on adverse events (as measured by intervention\u2010related mortality). Study limitations, inconsistency, and imprecision reduced our confidence in the effect estimates. Interpretation of these findings is highly sensitive to the choice of MCID. Emerging alternatives, such as screening with a kallikrein panel and MRI, may have little to no effect on diagnoses of prostate cancer, but the results on mortality are not yet known.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70455","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:22:50Z","timestamp":1790857370000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The\n                    <scp>PSA<\/scp>\n                    test for prostate cancer screening: an abridged Cochrane review"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-899X","authenticated-orcid":false,"given":"Juan V. A.","family":"Franco","sequence":"first","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK \u2013 D\u00fcsseldorf Subunit Centre for Health and Society, Institute of General Practice, Heinrich Heine University D\u00fcsseldorf  D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2031-124X","authenticated-orcid":false,"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology Chonnam National University Medical School, Chonnam National University Hwasun Hospital  Hwasun South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hung","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Urology Yonsei University Wonju College of Medicine  Wonju South Korea"},{"name":"Center of Evidence\u2010Based Medicine Institute of Convergence Science, Yonsei University  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9612-5807","authenticated-orcid":false,"given":"Octavio","family":"Vaimberg","sequence":"additional","affiliation":[{"name":"School of Medicine Universidad del Hospital Italiano de Buenos Aires  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-9185","authenticated-orcid":false,"given":"Dragan","family":"Ilic","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine School of Public Health and Preventive Medicine, Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cleves","sequence":"additional","affiliation":[{"name":"Velindre NHS Trust Library Services, Cardiff University  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-2553","authenticated-orcid":false,"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section Minneapolis VA Health Care System  Minneapolis MN USA"},{"name":"Department of Urology University of Minnesota  Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.013"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04232.x"},{"key":"e_1_2_10_5_1","unstructured":"CornfordP TilkiD Van den BerghRet\u00a0al.EAU \u2010 EANM \u2010 ESTRO ESUR \u2010 ISUP \u2010 SIOG Guidelines on Prostate Cancer. Available at:https:\/\/uroweborg\/guidelines\/prostate\u2010cancer. Accessed prior to 7 April 2026."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002757"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.022"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075819"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407934"},{"key":"e_1_2_10_11_1","first-page":"CD012663","article-title":"Prostate MRI, with or without MRI\u2010targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost F","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4200","article-title":"Future of screening for prostate cancer","volume":"358","author":"Dahm P","year":"2017","journal-title":"BMJ"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2012"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720.pub3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20017"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"d1539","DOI":"10.1136\/bmj.d1539","article-title":"Randomised prostate cancer screening trial: 20\u2010year follow\u2010up","volume":"342","author":"Sandblom G","year":"2011","journal-title":"BMJ"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr500"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.01.080"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0154"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3712"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21446"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003491"},{"key":"e_1_2_10_24_1","unstructured":"NG131: Prostate cancer: diagnosis and management; updated 2021. Available at:https:\/\/wwwniceorguk\/guidance\/ng131. Accessed prior to 8 April 2026."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3841"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_10_28_1","volume-title":"Methodological Expectations of Cochrane Intervention Reviews","author":"Higgins J","year":"2016"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720"},{"key":"e_1_2_10_30_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017)","author":"Higgins P","year":"2017"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209454"},{"key":"e_1_2_10_33_1","unstructured":"China Randomized Study of Screening for Prostate Cancer. Available at:https:\/\/wwwchictrorgcn\/showprojhtml?proj=255823. Accessed 28 January 2026."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00003"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3581"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153417"},{"key":"e_1_2_10_37_1","unstructured":"Prostate cancer screening with a PSA test: IQWiG Reports \u2013 Commission No. S19\u201001. Available at:https:\/\/wwwncbinlmnihgov\/books\/NBK558459\/. Accessed June 2020."},{"key":"e_1_2_10_38_1","unstructured":"Screening for prostate cancer: external review against programme appraisal criteria for the UK National Screening Committee.2020. Available at:https:\/\/view\u2010health\u2010screening\u2010recommendationsservicegovuk\/prostate\u2010cancer\/. Accessed 05 May 2025."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0763"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001431.pub6"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7624"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"e_1_2_10_44_1","unstructured":"S3 Guideline: Prostate cancer\u2014Long version 8.1. Available at:https:\/\/hubleitlinienprogramm\u2010onkologiede\/leitlinie\/prostatakarzinom. Accessed prior to 7 April 2026."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.02.009"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70455","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:22:54Z","timestamp":1790857374000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":46,"alternative-id":["10.1111\/bju.70455"],"URL":"https:\/\/doi.org\/10.1111\/bju.70455","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"2026-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70455"}}